Sivera, Francisca2; Andrés, Mariano2; Carmona, Loreto2; Kydd, Alison S R2; Moi, John2; Seth, Rakhi2; Sriranganathan, Melonie2; van Durme, Caroline2; van Echteld, Irene2; Vinik, Ophir2; Wechalekar, Mihir D2; Aletaha, Daniel2; Bombardier, Claire2; Buchbinder, Rachelle2; Edwards, Christopher J2; Landewé, Robert B2; Bijlsma, Johannes W2; Branco, Jaime C2; Burgos-Vargas, Rubén2; Catrina, Anca I2; Elewaut, Dirk2; Ferrari, Antonio J L2; Kiely, Patrick2; Leeb, Burkhard F2; Montecucco, Carlomaurizio2; Müller-Ladner, Ulf2; Østergaard, Mikkel1; Zochling, Jane2; Falzon, Louise2; van der Heijde, Désirée M2
1 Videncenter for Reumatologi og Rygsygdomme, HovedOrtoCentret Rigshospitalet, Rigshospitalet, The Capital Region of Denmark2 unknown
integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative
We aimed to develop evidence-based multinational recommendations for the diagnosis and management of gout. Using a formal voting process, a panel of 78 international rheumatologists developed 10 key clinical questions pertinent to the diagnosis and management of gout. Each question was investigated with a systematic literature review. Medline, Embase, Cochrane CENTRAL and abstracts from 2010-2011 European League Against Rheumatism and American College of Rheumatology meetings were searched in each review. Relevant studies were independently reviewed by two individuals for data extraction and synthesis and risk of bias assessment. Using this evidence, rheumatologists from 14 countries (Europe, South America and Australasia) developed national recommendations. After rounds of discussion and voting, multinational recommendations were formulated. Each recommendation was graded according to the level of evidence. Agreement and potential impact on clinical practice were assessed. Combining evidence and clinical expertise, 10 recommendations were produced. One recommendation referred to the diagnosis of gout, two referred to cardiovascular and renal comorbidities, six focused on different aspects of the management of gout (including drug treatment and monitoring), and the last recommendation referred to the management of asymptomatic hyperuricaemia. The level of agreement with the recommendations ranged from 8.1 to 9.2 (mean 8.7) on a 1-10 scale, with 10 representing full agreement. Ten recommendations on the diagnosis and management of gout were established. They are evidence-based and supported by a large panel of rheumatologists from 14 countries, enhancing their utility in clinical practice.
Annals of the Rheumatic Diseases, 2014, Vol 73, Issue 2, p. 328-35